Article: Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis.

BOTHELL, Wash. and CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. , a leader in developing therapeutics using advanced drug delivery technologies, and Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company , announced today a collaboration to develop and commercialize Nastech's Parathyroid Hormone (PTH1-34) nasal spray for the treatment of osteoporosis. Clinical and non-clinical studies on PTH1-34 nasal spray are currently being completed in preparation for Phase III clinical development.

Under terms of the agreement, Nastech will grant P&G rights to the worldwide development and commercialization of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!